Results 21 to 30 of about 10,843,123 (260)

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis [PDF]

Lancet Neurology, The, 2012
Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H).
Anton Porsteinsson, Stephen Salloway, Nick Fox   +2 more
exaly   +4 more sources

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer’s disease and a literature review [PDF]

BMC Neurology
Objective To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease (AD) patients treated with lecanemab.
Yingte Wang, Qun Yu, Bin Chen, Jing Zhou, Zhiming Li, Wang Liao, Jun Liu, Airong Yang   +7 more
doaj   +2 more sources

Amyloid‐related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid‐modifying therapy [PDF]

Annals of Clinical and Translational Neurology
Amyloid‐related imaging abnormalities, were originally described by dementia care experts. The wider use of aducanumab and now lecanemab warrant broader understanding by the health care provider continuum.
Rade B. Vukmir
doaj   +2 more sources

The Use of Portable MRI in the Detection and Monitoring of Amyloid‐Related Imaging Abnormalities [PDF]

Alzheimers Dement
Abstract Background Lecanemab is an anti‐beta‐amyloid immunotherapy approved by the FDA in 2023 for Alzheimer's Disease (AD). One known side effect is the development of amyloid‐related imaging abnormalities (ARIA), manifesting as cerebral edema (ARIA‐E), or microhemorrhage with siderosis (ARIA‐
Sharifi K, Hu J, Shimony H, Nagy S, Okafor J, Joseph‐Mathurin N, Banks J, Jarman S, Knopp E, Paczynski M, Venuto A, Lim J, Ghoshal N, Snider B, Benzinger T.   +14 more
europepmc   +4 more sources

Zooming in on Cerebral Amyloid Angiopathy in the Context of Amyloid-Related Imaging Abnormalities [PDF]

Innov Aging
Abstract The significance of cerebral amyloid angiopathy (CAA) has been heightened since anti-amyloid therapies were approved. Amyloid-related imaging abnormalities (ARIA) are a major side effect of anti-amyloid therapies, and CAA is the major risk factor for ARIA. CAA is highly prevalent in Alzheimer’s disease, and both are driven by
Sin, Mo-Kyung, Luo, Yuan
europepmc   +2 more sources

Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab. [PDF]

Alzheimers Dement
AbstractINTRODUCTIONAnti‐amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer's disease (AD). These therapies are associated with a high rate of amyloid‐related imaging abnormalities (ARIA).METHODSWe review the case history of a patient who developed ARIA associated with lecanemab treatment.RESULTSIn addition to ...
Gibson AW, Elser H, Rosso M, Cornblath EJ, Fonkeu Y, Prasad S, Rothstein A, Nasrallah IM, Wolk DA, Guo MH.   +9 more
europepmc   +3 more sources

Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease. [PDF]

Dtsch Arztebl Int
Vöglein J, Levin J, Brendel M.
europepmc   +2 more sources

Amyloid-Related Imaging Abnormalities Associated With Immunotherapy In Alzheimer‘s Disease Patients

Future Neurology, 2012
Evaluation of: Sperling R, Salloway S, Brooks DJ et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11(3), 241–249 (2012). Amyloid-related imaging abnormalities (ARIAs) have been reported in patients with Alzheimer’s disease treated with bapineuzumab, a ...
Davide Seripa, Simone Dini, Bruno Imbimbo   +2 more
exaly   +2 more sources

ED care and Amyloid‐Related Imaging Abnormalities ‐ Impact and Future research [PDF]

Alzheimers Dement
AbstractWith the approval of disease modifying treatments for Alzheimer’s Disease, the practice of dementia care and treatment has changed. Amyloid related imaging changes, are the most common adverse effects of these types of drugs. There is limited guidance across multiple specialties on how to recognize and manage these changes in a dementia patient
Aggarwal N, Carpenter C.
europepmc   +2 more sources

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.

JAMA Neurol
ImportanceData from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.ObjectivesTo describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).Design, Setting,
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R.   +16 more
europepmc   +5 more sources